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Abstract
Background: The evaluation of infant meconium as a cumulative matrix of prenatal toxicant exposure requires
comparison to established biomarkers of prenatal exposure.
Methods: We calculated the frequency of detection and concentration of tobacco smoke metabolites measured in
meconium (nicotine, cotinine, and trans-3′-hydroxycotinine concentrations) and three serial serum cotinine
concentrations taken during the latter two-thirds of pregnancy among 337 mother-infant dyads. We estimated the
duration and intensity of prenatal tobacco smoke exposure using serial serum cotinine concentrations and
calculated geometric mean meconium tobacco smoke metabolite concentrations according to prenatal exposure.
We also compared the estimated associations between these prenatal biomarkers and infant birth weight using
linear regression.
Results: We detected nicotine (80%), cotinine (69%), and trans-3′-hydroxycotinine (57%) in most meconium
samples. Meconium tobacco smoke metabolite concentrations were positively associated with serum cotinine
concentrations and increased with the number of serum cotinine measurements consistent with secondhand or
active tobacco smoke exposure. Like serum cotinine, meconium tobacco smoke metabolites were inversely
associated with birth weight.
Conclusions: Meconium is a useful biological matrix for measuring prenatal tobacco smoke exposure and could
be used in epidemiological studies that enroll women and infants at birth. Meconium holds promise as a
biological matrix for measuring the intensity and duration of environmental toxicant exposure and future studies
should validate the utility of meconium using other environmental toxicants.
Introduction
Fetal meconium is formed beginning in the 13
th week of
gestation from swallowed amniotic fluid, shed epithelial
cells, and intestinal secretions [1]. Meconium may be
metabolically inert and concentrations of drugs and
other toxicants are thought to represent cumulative
gestational exposure over the latter two-thirds of preg-
nancy [1]. Ostrea and colleagues have reported that
meconium is a sensitive matrix for measuring markers
of gestational drug use and prenatal pesticide exposure
[2-6].
Prenatal active and secondhand tobacco smoke expo-
sure is a prevalent environmental exposure that is asso-
ciated with adverse infant and childhood health
outcomes [7,8]. Several studies have detected and quan-
tified tobacco smoke metabolites including nicotine
(NIC), cotinine (COT), and trans-3′-hydroxycotinine
(3HC) in infant meconium samples [3,9-12]. In adult
humans, 70 to 80% of inhaled nicotine (NIC) from
tobacco smoke is metabolized into cotinine (COT) and
* Correspondence: jbraun@hsph.harvard.edu
1Department of Epidemiology, University of North Carolina-Chapel Hill,
Chapel Hill, NC, 27599-7435, USA
Full list of author information is available at the end of the article
Braun et al. Environmental Health 2010, 9:53
http://www.ehjournal.net/content/9/1/53
© 2010 Braun et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.50% of COT is metabolized into trans-3′-hydroxycoti-
nine (3HC) [13]. Comparable percentages of nicotine
and other tobacco smoke constituents can cross the pla-
centa and have been measured in the fetus [14].
Results from prior studies indicate that meconium
NIC, COT, and 3HC concentrations are correlated with
maternal report of tobacco smoke exposure. However it
is unclear if meconium tobacco smoke metabolites
reflect the intensity and duration of prenatal tobacco
smoke exposure since prior studies have used self-report
or biomarkers of tobacco smoke exposure at birth to
represent gestational exposures [3,11,15]. Two studies
have attempted to determine if meconium tobacco
smoke metabolites are reflective of prenatal secondhand
tobacco smoke (SHS) exposures and both have been
limited by small sample sizes [11,15]
Two studies have examined the association between
meconium tobacco smoke metabolite concentrations
and childhood health outcomes [12,16]. Gray and collea-
gues reported decrements in birth weight, length, and
head circumference among infants with detectable
meconium tobacco smoke metabolite concentrations.
Nuesslein et al. found a positive association between
meconium cotinine concentrations and risk of respira-
tory infections in the first year of life. Both studies were
relatively small and did not have other biomarkers of
tobacco smoke exposure that allowed for comparison to
meconium results.
Given the interest in using meconium as a biological
matrix to measure prenatal toxicant exposure in epide-
miological studies like the National Children’sS t u d y
[17], the utility of meconium should be validated in
reference to well established biomarkers of gestational
exposure. We examined the utility of meconium as a
biological matrix of prenatal tobacco smoke exposure
using two approaches in the Health Outcomes and Mea-
sures of the Environment (HOME) Study. First, we
examined the association between meconium tobacco
smoke metabolites and serial self-report and serum coti-
nine biomarkers of prenatal tobacco smoke exposure.
Second, we evaluated whether the two biomarkers
(meconium tobacco smoke metabolites and serum coti-
nine) would produce similar results when investigating
the association between prenatal tobacco smoke expo-
sure and infant birth weight.
Methods
Study Sample
We used data collected from mothers and their infants
participating in the HOME Study, an ongoing prospec-
tive birth cohort in the Cincinnati metropolitan area
designed to examine low-level environmental toxicant
exposure and the efficacy of injury and lead hazard con-
trols in the home. From March of 2003 to January 2006,
women were identified from seven prenatal clinics asso-
ciated with three hospitals. Eligibility criteria for the
study included: <19 weeks gestation; > 18 years old; living
in a house built before 1978; living in Brown, Butler,
Clermont, Hamilton, or Warren counties, intention to
continue prenatal care and deliver at collaborating obste-
tric practices, negative HIV status; and not receiving sei-
zure, thyroid, or chemotherapy/radiation medications.
We mailed letters to 5,512 women > 18 years of age who
were living in a home built before 1978 to see if they
were eligible and interested in participating in our study.
Of the 1,263 eligible women, 468 enrolled in our study.
Our analyses were restricted to singleton infants.
Tobacco Smoke Measurements
Self-Reported Exposure
Women self-reported secondhand and active tobacco
smoke exposures for the periods between conception
and 20 weeks (measured at 20 week home visit) and 20
weeks and birth (measured at a 4 week postpartum
visit). Trained interviewers asked the women the average
number of cigarettes they smoked per day, the number
of smokers living in the home, and the number of cigar-
ettes smoked per day by other people in the home for
each time period. We classified the woman’se x p o s u r e
status during each time period as unexposed, exposed to
secondhand tobacco smoke, and exposed to active
tobacco smoke.
Serum and Meconium Biomarkers of Exposure
Women provided serum samples at 16 weeks gestation,
26 weeks gestation, and within 24 hours of birth. All
samples were stored at -20°C until they were transported
to the Centers for Disease Control and Prevention (CDC)
l a b o r a t o r yf o ra n a l y s i s ,w h e r et h e yw e r es t o r e da t
< -20°C. Serum samples were analyzed for cotinine, a bio-
marker of nicotine exposure, using high performance
liquid chromatography-tandem mass spectrometry
(HPLC-MS/MS) [18,19]. The limit of detection (LOD)
for this assay was 0.015 ng/mL with a coefficient of varia-
tion (CV) ranging from 3-4% at high concentrations
(1 ng/mL) to 10% at low concentrations (0.1 ng/mL).
Meconium specimens were collected from infants dur-
ing their hospital stay by placing cellulose fiber inserts
inside infant diapers. After it was soiled, the diaper and
insert were initially stored in a labeled plastic bag in a
designated hospital refrigerator until they were collected
by study staff, usually within 24 hours. Meconium stools
were collected throughout the hospital stay, until the
first milk stool appeared. Study staff pooled meconium
samples from diapers into polyethylene containers using
a spatula. Pooled meconium samples were stored at
-20°C until transported to CDC laboratories where they
were stored at < -20°C. Study staff took care not to col-
lect fibers from the diaper or cellulose insert.
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were digested at room temperature in 3 mL of 5 N
potassium hydroxide containing the internal standards
(trideuterated nicotine, cotinine and hydroxycotinine;
1.25 ng of each per sample except for nicotine which
was 5 ng). The digested material was extracted with
methylene chloride and ethanol, back-extracted into
hydrochloric acid, neutralized, buffered, and applied to a
CleanScreen DAU column which was processed essen-
tially as described by Ostrea et al [4]. HPLC-MS/MS
was used to quantify the concentrations of the NIC,
COT, and 3HC relative to the deuterated internal stan-
dards. Samples were analyzed using multiple reaction
monitoring and concentrations were calculated from the
ratios of native and labeled ions in the samples com-
pared to a 10-point calibration curve incorporating the
three analytes. Transition ions monitored in this work
were 192.9/80.0 and 192.9/133.9 for hydroxycotinine,
177/98.1 and 177/80.1 for cotinine, and 162.9/130,
162.9/117 for nicotine. Corresponding single transitions
were monitored for each internal standard. The LODs
for these three compounds were 0.946 ng/g for NIC,
0.070 ng/g for COT, and 0.092 ng/g for 3HC.
Each analytical run included two blank samples and a
low and high concentration quality control (QC) sample.
The low and high QC materials were prepared from two
separate, pooled samples of meconium that had been
pre-tested and confirmed to have different levels of all
three metabolites present. Each pool was prepared by
taking 25 g of its respective meconium sample and
diluting with 600 mL 5 N KOH. This was allowed to
stir for 2 hr to dissolve the solid and assure even mix-
ing. Each pool was dispensed with continuous mixing in
3 mL aliquots into 200 sequentially numbered 16 × 125
mm screw cap tubes. After all the tubes were prepared,
they were stored at -70°C until use. The low-concentra-
tion QC samples had a relative standard deviation
(RSD) of 25% (NIC), 8% (COT), and 14% (3HC), while
the high-concentration QC samples had a CV of 15%
(NIC), 5% (COT), and 6% (3HC). Accuracy evaluations
were conducted at target concentrations of 0.5, 2.5 and
7.5 ng/g (2, 10 and 30 ng/g for nicotine). All samples
had an analytical bias of less than ± 10%.
Infant Birth Weight and Covariates
Infant birth weight (in grams) was abstracted from hospital
medical records and was analyzed as a continuous variable.
Maternal age, race, education, and marital status were
gathered at the first prenatal care visit. Maternal depres-
sion was assessed using the Beck Depression Inventory-II
(BDI-II) which was administered during a home visit at
approximately 20 weeks [20]. Parity was obtained from
maternal medical records. Maternal weight (in kg) was col-
lected at the initial clinic visit at 16 weeks gestation.
Statistical Analysis
We conducted our statistical analysis in two stages. First
we examined the relationship between the various self-
report and biomarkers of prenatal tobacco smoke
exposure. Second, we examined and compared the asso-
ciation between meconium and serum biomarkers of
tobacco smoke exposure and infant birth weight.
We started our statisticala n a l y s i sb yc o m p a r i n g
women and infants with complete meconium, self-
report, serum, and birth weight data to women with
missing data. We corrected for the right-skewed distri-
bution of serum cotinine and meconium tobacco smoke
metabolite concentrations using the log10-transformation
in analyses using continuous variables. Serum and
meconium cotinine values <LOD were randomly
imputed from the left tail of the log10-normal distribu-
tion [21].
Relationship between Self-Report and Biomarkers of
Tobacco Smoke Exposure
We compared methods of classifying tobacco smoke
exposures among mother-infant pairs with at least two
prenatal serum cotinine measurements and a valid
meconium measurement available. We created several
measures of cumulative prenatal tobacco smoke expo-
sure using either self-reported tobacco smoke exposure
or prenatal serum cotinine concentrations.
First, we created a summary variable of self-reported
prenatal tobacco smoke exposure over the course of
pregnancy. This five category variable reflected the level
and duration of exposure: unexposed, SHS exposure in
o n ep e r i o d ,S H Se x p o s u r ei nb oth periods, active expo-
sure in one period (the other period was unexposed or
SHS exposure), and active exposure in both periods.
Next, we averaged the available serum cotinine mea-
surements to create a continuous summary measure
women’s prenatal tobacco smoke exposure between 16
weeks gestation and birth. From this, we created cate-
gories of unexposed (< LOD), secondhand exposure
(LOD to 3 ng/mL), and active exposure (> 3 ng/mL).
The threshold of 3 ng/mL for active smoking was cho-
sen based on results from the 1999-2004 National
Health and Nutrition Examination Survey which com-
pared self-reported smoking status and serum cotinine
levels among a representative sample of the US popula-
tion [22].
Among women with all three serum cotinine and
meconium measurements, we further quantified cumu-
lative exposure to prenatal tobacco smoke by creating a
summary variable that described the number of prenatal
serum measurements that a woman was exposed to sec-
ondhand or active tobacco smoke. This seven category,
ordinal variable counted the number of measurements
that a woman had serum cotinine concentrations indica-
tive of secondhand (zero, one, two, or three) or active
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any of the secondhand categories could not have had
active exposure at another time point, while women in
the active categories could have had another serum
measurement consistent with secondhand or no
exposure.
Finally, we investigated whether the timing of the
serum measurements influenced the association between
the number of serum cotinine measurements indicative
of secondhand or active tobacco smoke exposure and
meconium NIC concentrations. We did this using a
seven category variable that summarized the number
and timing of serum cotinine concentrations consistent
with secondhand and active tobacco smoke exposure at
1 6w e e k sa n db i r t h .W el i m i t e dt h i sa n a l y s i st oN I C
concentrations because NIC was detected most fre-
quently and the results with NIC concentrations were
similar to those using COT and 3HC concentrations.
We calculated the geometric mean (GM) and corre-
sponding 95% confidence interval (CI) of meconium
tobacco smoke metabolite concentrations according to
self-reported and serum cotinine concentration cate-
gories described above. We also calculated the propor-
tion of infants with detectable meconium tobacco
smoke metabolite concentrations according to self-
reported or serum categories.
Association between Biomarkers of Prenatal Tobacco
Smoke Exposure and Infant Birth Weight
The second stage of our analysis examined the associa-
tion between biomarkers of tobacco smoke exposure
and infant birth weight. We chose to examine birth
weight because there is a well-established inverse rela-
tionship between serum cotinine concentrations and
infant birth weight [23-28].
We compared the results for the different biomarkers
of tobacco smoke exposure since many cohorts only
have the resources to collect one exposure measure-
ment. We estimated and compared the associations
between continuous log10-transformed prenatal serum
cotinine and meconium tobacco smoke metabolite con-
centrations and infant birth weight using linear regres-
sion. Coefficients from these analyses represent the
mean change in infant birth outcome for a 10-fold
increase in tobacco smoke biomarker concentration. In
addition, we examined the association between categori-
cal serum and meconium tobacco smoke metabolite
concentrations and infant birth weight. Serum cotinine
concentrations were categorized using the thresholds
described above. Several different meconium tobacco
smoke metabolite concentrations were used to discrimi-
nate secondhand from active tobacco smoke exposure
based on sensitivity and specificity analyses.
In all of the analyses examining the association
between prenatal tobacco smoke exposure and infant
birth weight, we adjusted for confounders identified
using a directed acyclic graph (DAG) [29]. DAGs are a
better method to assess the role of confounding vari-
ables compared to change in estimate and significance
testing approaches [30]. Based on our DAG, all models
included maternal age, maternal education, maternal
race, marital status, depression (), and maternal weight
(kg). We did not adjust for gestational age since it was
an intermediary on the causal pathway between prenatal
tobacco smoke exposure and infant birth outcomes.
Ethical Considerations
The Institutional Review Boards (IRB) of the University
of North Carolina-Chapel Hill, Cincinnati Children’s
Hospital and Medical Center, and CDC approved this
study. The Cincinnati Children’s Hospital and Medical
Center IRB was involved in the oversight of this study.
All mothers provided written informed consent for
themselves and their children prior to enrollment in the
study.
Results
Of the 468 women who enrolled in our study, 67 dropped
out before delivery. We excluded 9 children from sets of
twins and 3 still-born infants, leaving 389 infants. A total
of 326 women and infants (83.8%) had at least two prena-
tal serum measurements and a meconium measurement
available, many (n = 284, 73.0%) had all three prenatal
serum measurements and a meconium measurement.
Complete self-reported tobacco smoke exposure and
meconium data was available for 316 (81.2%) women.
Women with complete data were better educated, non-
Hispanic white, married, and 25-34 years of age compared
to women with incomplete data (Table 1).
Relationship between Self-Report and Biomarkers of
Tobacco Smoke Exposure
NIC, COT, and 3HC were detected in 80.1, 69.6, and
56.4% of infant meconium samples, respectively; 90.2% of
samples had at least one detectable metabolite (Table 2).
Sixty-one percent of women had mean serum cotinine
concentrations > LOD and 88.9% had at least one detect-
able serum cotinine concentration between 16 weeks
gestation and birth. Geometric mean meconium tobacco
smoke metabolite concentrations were highest for NIC
(GM: 2.40 ng/g; 95% CI: 2.08, 2.78) and lower for COT
(GM: 0.19 ng/g; 95% CI: 0.15, 0.24) and 3HC (GM:
0.17 ng/g; 95% CI: 0.13, 0.23). Seventy-five percent of
women with mean serum cotinine concentration <LOD
gave birth to infants with at least one detectable meco-
nium tobacco smoke metabolite.
Serum cotinine measures were highly correlated with
each other (Pearson R~0.7-0.9). Meconium tobacco
smoke metabolite concentrations were also highly
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0.79), NIC and 3HC (Pearson R = 0.72), and COT and
3HC (Pearson R = 0.85). Mean serum cotinine and
meconium metabolite concentrations were also highly
correlated: NIC (Pearson R = 0.59), COT (Pearson R =
0.72), and 3HC (Pearson R = 0.71). The RSDs for the
meconium tobacco smoke metabolite analyses (10-30%)
were approximately 3 times higher than the RSDs for
our serum metabolite analyses (3-10%).
Self-reported tobacco smoke exposures were positively
associated with mean and detectable meconium tobacco
smoke metabolite concentrations (Table 3). Compared
to unexposed infants, women self-reporting SHS expo-
sure gave birth to infants with slightly higher meconium
nicotine concentrations and those reporting active
smoking gave birth to infants with meconium nicotine
concentrations 1 to 3 orders of magnitude higher.
Meconium COT and 3HC concentrations were similar
among women with self-report of secondhand or no
tobacco smoke exposures, but higher among self-
reported active smokers.
Infant meconium tobacco smoke metabolite concentra-
tions were greater when mother’s mean serum cotinine
concentrations indicated secondhand and active tobacco
smoke exposure rather than no exposure (Table 3). All
three meconium tobacco smoke metabolites were
detected in essentially all infants born to women with
mean serum cotinine concentrations > 3 ng/mL.
Meconium tobacco smoke metabolite concentrations
increased with the number of serum cotinine measure-
ments indicative of secondhand or active tobacco smoke
exposure (Table 3). However, there was little difference
in meconium tobacco smoke metabolite concentrations
among infants born to women with one or two serum
measurements indicative of SHS exposure (Figure 1).
Infant meconium tobacco smoke metabolite concentra-
tions were about 2 times higher in women with three
serum measurements indicative of SHS compared to
women with no tobacco smoke exposure. Relative to
differences in meconium NIC concentrations, meconium
COT and 3HC concentrations were higher among active
smokers and women with three serum measurements
Table 1 Distribution of demographic variables among mothers/infants in HOME study
Variable All Women
N = 389 (%)
Women with All Data N = 315 (%) * Women Missing Any Data N = 74 (%)
Maternal Race
White 237 (61.7) 209 (66.4) 28 (40.6)
Black 121 (31.5) 86 (27.3) 35 (50.7)
Other 26 (6.8) 20 (6.3) 6 (8.7)
Missing 5 0 5
Maternal Education (years)
< 12 41 (10.7) 23 (7.3) 18 (26.1)
12 54 (13.8) 41 (13.0) 13 (18.8)
> 12 289 (74.5) 251 (79.7) 38 (55.1)
Missing 5 0 5
Marital Status
Married 248 (64.6) 217 (68.9) 31 (44.9)
Single 136 (35.4) 98 (31.1) 38 (55.1)
Missing 5 0 5
Maternal Age Category (years)
< 25 96 (24.7) 63 (20.0) 33 (44.6)
25-34 231 (59.4) 197 (62.5) 34 (45.9)
35+ 62 (15.9) 55 (17.5) 7 (9.5)
Missing 0 0 0
*Women had all 3 serum cotinine measurements, both self-reported tobacco smoke interviews, meconium measurement, and infant birth outcome data.
Table 2 Descriptive statistics of meconium and serum tobacco smoke metabolite concentrations
Metabolite N % Detected Minimum 5
th 25
th Median 75
th 95
th Maximum
Meconium NIC 331 80.1 < LOD < LOD 1.06 2.02 4.14 48.2 301
Meconium COT 339 69.6 < LOD < LOD < LOD 0.12 0.40 33.5 313
Meconium HCOT 335 56.4 < LOD < LOD < LOD 0.10 0.52 51.2 324
Serum COT 338 61.2 < LOD < LOD < LOD 0.02 0.21 62.8 356
*-Meconium concentrations are ng/g and serum concentrations are ng/mL
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exposure.
Secondhand or active tobacco exposures in later preg-
nancy resulted in greater increases in meconium NIC
concentrations than exposures earlier in pregnancy (Fig-
ure 2). After adjustment for 26-week serum cotinine
concentrations, meconium NIC concentrations were
higher among infants born to women with serum coti-
nine concentrations indicative of SHS exposure at birth
only (GM: 2.71; 95% CI: 1.65, 4.43) compared to infants
born to women with serum cotinine concentrations
indicative of SHS exposure at 16 weeks only (GM: 1.77;
95% CI: 1.26, 2.48).
Association between Biomarkers of Prenatal Tobacco
Smoke Exposure and Infant Birth Weight
Of the meconium tobacco smoke metabolites, NIC pro-
vided the largest and least precise point estimates com-
pared to meconium COT and 3HC (Table 4). Of the
individual serum cotinine concentrations, birth serum
cotinine categories of prenatal tobacco smoke exposure
were the largest and most precise point estimates.
Meconium NIC concentrations provided estimates most
similar to mean prenatal serum cotinine concentrations
and birth serum cotinine concentrations. Categorical
meconium COT and 3HC estimates provided attenuated
associations relative to birth and mean serum cotinine
categories and meconium NIC categories.
Estimates between SHS exposure and birth weight
were similar when we evaluated different thresholds
for classifying SHS and active exposure using meco-
nium tobacco smoke metabolite concentrations. How-
ever, raising the threshold for active exposure (10 to
30 ng/g) increased NIC point estimates between active
smoking and birth weight and raising the threshold
for COT (5 to 10 ng/g) and 3HC (10 to 30 ng/g)
decreased the point estimate between active smoking
and birth weight.
Discussion
The two sets of analyses presented suggest that meco-
nium can be used as a biological matrix to measure pre-
natal tobacco smoke exposure. Meconium tobacco
smoke metabolites were positively associated with self-
report and serum biomarkers of prenatal tobacco smoke
exposure. We observed a dose-dependent relationship
between the number of serum cotinine measurements
consistent with secondhand or active tobacco smoke
exposure during the latter two-thirds of pregnancy and
meconium tobacco smoke metabolite concentrations.
Our results indicate that tobacco smoke metabolites in
meconium reflect the duration and intensity of gesta-
tional exposure to tobacco smoke. Tobacco smoke
metabolites may accumulate in meconium differentially
across pregnancy since the bulk of meconium is formed
later in pregnancy.
Table 3 Geometric mean infant meconium tobacco smoke metabolite concentration by prenatal tobacco smoke
exposure
Meconium NIC Meconium COT Meconium 3HC
N % Detect GM
(95% CI)
% Detect GM
(95% CI)
% Detect GM
(95% CI)
By Self-Reported Exposure
Unexposed Both Periods 232 69.3 1.74 (1.50, 2.01) 60.3 0.10 (0.08, 0.12) 45.2 0.08 (0.06, 0.11)
SHS Exposure 1 Period 21 85.7 2.20 (1.35, 3.59) 95.2 0.27 (0.12, 0.62) 85.7 0.32 (0.13, 0.81)
SHS Exposure Both Periods 27 85.2 2.56 (1.67, 3.94) 77.8 0.20 (0.09, 0.40) 59.3 0.15 (0.07, 0.34)
Active Exposure 1 Period 15 86.7 4.34 (2.44, 7.73) 93.3 0.92 (0.35, 2.43) 86.7 0.91 (0.31, 2.68)
Active Exposure Both Periods 21 100 26.8 (16.6, 43.1) 100 15.9 (7.0, 36.2) 95.5 23.3 (9.5, 56.8)
By Mean Serum Cotinine
Unexposed (< LOD) 131 70.6 1.50 (1.24, 1.82) 48.1 0.07 (0.05, 0.09) 33.8 0.05 (0.04, 0.07)
SHS Exposure (LOD - 3 ng/mL) 170 83.9 2.08 (1.76, 2.45) 79.4 0.16 (0.12, 0.21) 65.3 0.15 (0.12, 0.21)
Active Exposure (> 3 ng/mL) 37 94.7 21.3 (15.0, 30.1) 100 16.8 (9.7, 29.0) 97.4 21.3 (11.5, 39.3)
By Cumulative Serum Cotinine
Unexposed all 3 Measures 61 71.2 1.32 (0.99, 1.76) 50 0.05 (0.03, 0.07) 30.0 0.03 (0.02, 0.05)
SHS Exposure in 1 Measure 61 65.5 1.57 (1.18, 2.10) 46.7 0.08 (0.05, 0.12) 40.0 0.07 (0.04, 0.11)
SHS Exposure in 2 Measures 41 71.8 1.70 (1.20, 2.42) 65 0.09 (0.05, 0.14) 40.0 0.07 (0.04, 0.12)
SHS Exposure in 3 Measures 92 89.2 2.41 (1.92, 3.03) 89.4 0.19 (0.14, 0.26) 72.5 0.18 (0.12, 0.27)
Active Exposure in 1 Measure 14 92.9 4.87 (2.71, 8.75) 100 2.77 (1.20, 6.37) 92.9 1.98 (0.75, 5.25)
Active Exposure in 2 Measures 3 100 24.6 (6.92, 87.3) 100 13.3 (2.20, 80.5) 100 20.6 (2.50, 170)
Active Exposure in 3 Measures 22 95.6 27.6 (17.5, 43.7) 100 20.6 (10.6, 40.0) 100 32.3 (15.1, 69.3)
Concentration in ng/g
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Page 6 of 11Figure 1 Geometric mean meconium tobacco smoke metabolite concentration by duration and intensity of prenatal tobacco smoke
exposure. Unexposed indicates all three prenatal serum cotinine measurements were <LOD. 1X, 2X, and 3X indicate the number of serum
cotinine measurements consistent with secondhand or active tobacco smoke exposure. Error bars represent 95% CI of the geometric mean.
Figure 2 Adjusted geometric mean meconium nicotine concentration by 16 week and birth serum cotinine category*. *-Adjusted for 26
weeks serum cotinine category (< LOD, LOD - 3 ng/mL, and > 3 ng/mL). Error bars represent 95% CI of the geometric mean.
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and almost universally detected among infants born to
active smokers compared to women with secondhand or
no exposure. Meconium COT and 3HC concentrations
may be a more sensitive biomarker of active prenatal
tobacco smoke exposures, while meconium NIC concen-
trations may be a more sensitive marker of secondhand
exposures since they were detected more frequently
among infants with secondhand or no tobacco smoke
exposure. An additional advantage to meconium NIC is
that the higher frequency of detection reduces the need
to impute left-censored data [21].
Meconium may be a more sensitive matrix to measure
prenatal tobacco smoke exposure than serum if it
Table 4 Adjusted association between serum and meconium biomarkers of tobacco smoke exposure and infant birth
weight*
N Mean Birth Weight Change in Birth Weight
(95% CI)
Confidence Limit Difference†
Meconium NIC
Unexposed (< LOD) 62 3386 Ref —
SHS (LOD - 10 ng/g) 212 3251 -136 (-295, 24) 320
Active (> 10 ng/g) 28 3252 -135 (-395, 126) 520
Continuous† 302 — -62 (-178, 53) 231
Meconium COT
Unexposed (< LOD) 97 3317 Ref —
SHS (LOD - 5 ng/g) 171 3286 -27 (-175, 120) 295
Active (> 5 ng/g) 34 3207 -106 (-348, 135) 482
Continuous† 302 — -61 (-132, 10) 143
Meconium 3HC
Unexposed (< LOD) 135 3335 Ref —
SHS (LOD - 10 ng/g) 139 3235 -100 (-246, 46) 292
Active (> 10 ng/g) 28 3278 -57 (-307, 192) 500
Continuous† 302 — -30 (-96, 36) 132
Mean Serum COT
Unexposed (< LOD) 122 3377 Reference —
SHS (LOD to 3 ng/mL) 148 3265 -112 (-264, 41) 305
Active (> 3 ng/mL) 32 3188 -189 (-462, 84) 545
Continuous† 302 — -60 (-135, 16) 150
16 Week Serum COT
Unexposed (< LOD) 101 3312 Reference —
SHS (LOD to 3 ng/mL) 162 3292 -20 (-173, 132) 305
Active (> 3 ng/mL) 32 3203 -109 (-386, 168) 554
Continuous† 295 — -59 (-125, 7) 132
26 Week Serum COT
Unexposed (< LOD) 126 3282 Reference —
SHS (LOD to 3 ng/mL) 138 3302 20 (-135, 175) 305
Active (> 3 ng/mL) 29 3144 -138 (-425, 150) 554
Continuous† 293 — -41 (-104, 21) 125
Birth Serum COT
Unexposed (< LOD) 121 3416 Reference —
SHS (LOD to 3 ng/mL) 131 3319 -97 (-248, 54) 302
Active (> 3 ng/mL) 29 3226 -190 (-462, 82) 545
Continuous† 281 — -40 (-104, 24) 128
*-Adjusted for maternal age (18 to <25, 25 to <35, and 35+ years), race (non-Hispanic white, non-Hispanic black, and other), education (< 12, 12, and >12 years),
martial status (married and unmarried), depression (minimal, mild, and moderate/severe), parity (0, 1, and >1) and maternal weight.
†-Calculated by subtracting the lower 95% confidence limit from the upper 95% confidence limit
‡-Coefficients represent change in birth weight for a 10-fold increase in metabolite concentration.
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individual or serial serum measurements. However, non-
detectable serum cotinine concentrations could be due
to increased nicotine and cotinine metabolism and
clearance during pregnancy [13,31]. Thus, women with
tobacco smoke exposures that are not detectable using
serum cotinine might give birth to infants with detect-
able meconium tobacco smoke metabolites. We were
not able to examine whether metabolic or genetic fac-
tors, like CYP2A6 enzyme activity, modified the rela-
tionship between tobacco smoke exposures and
meconium tobacco smoke metabolites [32,33].
We detected a higher proportion of some meconium
tobacco smoke metabolites than some previous studies
[9,11]. Our proportion of detectable meconium COT
and 3HC was similar to Gray and colleagues [12].
Another study reported almost universal meconium
COT detection among their study participants [16]. Var-
iations in study results could be due to differences in
meconium digestion/extraction, analytical chemistry
methods, or exposure characteristics of the targeted
study population.
Tobacco smoke exposures in later pregnancy may
cause greater increases in meconium tobacco smoke
metabolite concentrations relative to earlier exposures.
This complicates the interpretation of meconium meta-
bolite concentrations since they reflect the duration,
intensity, and timing of exposure. Differential accumula-
tion of tobacco smoke metabolites in meconium over
the course of pregnancy may be due to changes in
blood volume, kidney and liver metabolism, placental
perfusion, increased quantities of amniotic fluid ingested
by the infant later in gestation, or amount of meconium
formed in later gestation [34]. However, inferences
regarding the timing of tobacco smoke exposures are
based on a relatively small number of women and
infants with different temporal patterns of exposure.
We are not aware of previous studies that attempted
to validate meconium as a matrix for measuring biomar-
kers of prenatal tobacco smoke exposure using repeated
serum cotinine measures for comparison. Ostrea et al.
reported that meconium nicotine concentrations
increased with self-reported prenatal tobacco smoke
exposure intensity [3]. Kohler et al. reported higher
meconium NIC, COT, and 3HC concentrations among
women with greater duration of active smoking during
pregnancy compared to women who quit smoking ear-
lier in pregnancy, but these results were based on only
eleven women who quit smoking during pregnancy [11].
Serial serum cotinine measurements allowed us to more
accurately classify prenatal secondhand and active
tobacco smoke exposures than previous studies.
Both serum cotinine and meconium tobacco smoke
metabolite concentrations were inversely associated with
birth weight. The magnitude and precision of the point
estimates using meconium NIC concentrations was
similar to serum cotinine concentration estimates within
our cohort and to previous estimates of the association
between prenatal serum cotinine concentrations and
infant birth weight [23-27]. Categorical meconium COT
and 3HC point estimates were smaller in magnitude
relative to categorical meconium NIC and serum coti-
nine point estimates; however, point estimates using
continuous meconium tobacco smoke metabolite or
serum cotinine concentrations were very similar to one
another. Investigators may wish to use serum cotinine
measurements to quantify prenatal exposure since col-
lecting meconium samples will require hospital staff be
able and willing to properly collect and store meconium
samples.
There are some limitations to the presented results.
First, we considered mean prenatal serum cotinine con-
centrations as the gold standard for prenatal tobacco
smoke exposure in these analyses. Serum cotinine con-
c e n t r a t i o n sa r ear e a s o n a b l ec h o i c et oc o m p a r ean e w
biomarker of tobacco smoke exposure against since they
are a more sensitive marker of secondhand exposure
than self-report during pregnancy [35-37]. However, it
would have been ideal to compare meconium to another
long term biomarker of prenatal tobacco smoke expo-
sure like hair nicotine or cotinine.
The small number of actively smoking women in our
sample limited our ability to precisely estimate relation-
ships between prenatal tobacco smoke exposure and
meconium tobacco smoke metabolites among active
smokers. However, among the larger number of women
with SHS exposure, we did observe similar patterns of
association between the number serum cotinine mea-
surements indicative of SHS exposure and meconium
tobacco smoke metabolite concentrations.
Finally, women in our sample were from relatively
high socioeconomic background, which is associated
with decreased active and SHS exposure during preg-
nancy [35,36,38]. Thus, our results may not be general-
izable to samples from populations with lower
socioeconomic status who may have different exposure
distributions.
There are several advantages and disadvantages to
using meconium as a matrix to measure prenatal
tobacco smoke exposure in epidemiological studies.
First, meconium tobacco smoke metabolite concentra-
tions reflect the duration and intensity of prenatal expo-
sures, providing an accurate estimate of the dose of
tobacco smoke constituents received by the infant in the
latter part of pregnancy. In addition, meconium may be
a good matrix to measure transient prenatal tobacco
smoke exposures, as we detected nicotine in the meco-
nium of infants born to women with undetectable
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measurement indicative of secondhand or active tobacco
smoke exposure. However, meconium tobacco smoke
metabolite concentrations do not allow classification of
exposure during specific time periods of development.
Furthermore, elevated meconium tobacco smoke meta-
bolite concentrations may be due to constant exposure
over the entire course of pregnancy or high exposure in
the latter parts of pregnancy.
Second, meconium could be used as a matrix for bio-
markers of exposure in research studies that enroll
women at or shortly after parturition, but does require
additional resources to collect and analyze. While both
serum and meconium biomarkers provided similar esti-
mates of association with birth weight, investigators
should consider the additional resources necessary to
collect and analyze meconium samples, especially if
there are other well-developed biomarkers of exposure.
Meconium digestion and analysis, done at the CDC
laboratory, was more labor intensive and less efficient
than serum cotinine assays, taking approximately 4
times longer to complete.
Conclusions
Meconium tobacco smoke metabolites can be used to
measure the duration and intensity of prenatal tobacco
smoke exposure. However, investigators planning to use
meconium should consider whether meconium toxicant
concentrations will provide additional exposure informa-
tion not gleaned from other well-developed biomarkers
of exposure. For studies of prenatal tobacco smoke
exposure, meconium tobacco smoke metabolites do not
provide additional exposure information that would not
be captured by a single serum cotinine measurement.
Additional research should determine whether meco-
nium can be used estimate gestational exposure to other
environmental toxicants that exhibit more variability
during pregnancy, especially non-persistent compounds
like bisphenol A and phthalates. Future studies should
compare meconium and other validated biomarkers of
exposure with infant or child health outcomes in well
characterized exposure-outcome relations.
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